Hero decorative image
Hero Checkpoint Logo

A Breakthrough Approach in Cancer Therapy Development

Checkpoint Therapeutics is revolutionizing the way novel treatments for cancer patients are developed. As a fast-follower, our streamlined approach lowers risk and accelerates the development and commercialization of oncology drugs, ensuring more patients, payors and providers benefit from effective and potentially more affordable treatment options.

Learn more

A World Without Obstacles to Treat Cancer

Cancer affects many, yet the costs associated with the best treatment therapies continue to escalate. At Checkpoint Therapeutics, our mission is to improve the healthcare system by bringing to market potentially life-saving immunotherapy and targeted cancer treatments with speed, efficacy and at potentially lower prices compared to large pharmaceutical companies.

Fewer obstacles. Expanded access. Better patient outcomes. A brighter outlook for those with cancer.

Pipeline

Learn about our various candidates in different stages of development.

Learn More

Publications

Explore our reference articles and poster presentations.

Learn More

Investor Relations

View our latest corporate presentation and real-time stock information.

Learn More

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYTâ„¢ (cosibelimab-ipdl)

Read Article

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Read Article

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Read Article

Keep in touch

Stay up-to-date with our latest news and announcements.

Contact Us